ResearchingRefreshing ALNY from the latest filings.
1 of 8 sections ready
As of Sep 6, 2026, 2:25 PM
Price Chart
Overview
Alnylam Pharmaceuticals develops and sells medicines that switch off disease-causing genes using RNA interference, with a focus on rare genetic, heart, liver, and central-nervous-system diseases; as of July 30, 2026, it had six approved products. Its most important drug is AMVUTTRA (vutrisiran), an approved treatment for the full spectrum of transthyretin amyloidosis, while newer programs such as ALN-6400 and mivelsiran were in Phase 2 development as of July 30, 2026. Alnylam now makes money mainly from marketed-product sales, generating $1.172 billion of global net product revenue and $1.291 billion of total revenue in the quarter ended June 30, 2026, with GAAP net income of $164.5 million for that quarter; management guided to $4.2 billion-$4.5 billion of 2026 transthyretin product revenue for the fiscal year ending December 31, 2026.
The opportunity is a rapidly scaling commercial RNA-interference platform led by AMVUTTRA: transthyretin revenue was $1.030 billion in the quarter ended June 30, 2026, up 89% from the quarter ended June 30, 2025, and the company is expanding into additional genetic, cardiovascular, neurological, and metabolic diseases. The key risk is concentration and execution: the investment case depends heavily on continued AMVUTTRA growth, favorable reimbursement, successful late-stage pipeline results, regulatory approvals, manufacturing, and partner execution; Alnylam itself identifies these risks in its 2025 Form 10-K and 2026 second-quarter filing.